Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 CountriesJin-Lin Hou, Seng Gee Lim, Deming Tan et al.|Clinical Gastroenterology and Hepatology|2019Cited by 111
Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changesHaowen Qiao, Pu Chen, Moujian Guo et al.|PLoS Pathogens|2020Cited by 70
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label studyXiaoning Wu, Hong You, Yiwen Shi et al.|Expert Opinion on Biological Therapy|2018Cited by 44
On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in <scp>HBV</scp>‐related compensated cirrhosisShanshan Wu, Jidong Jia, Yuanyuan Kong et al.|Liver International|2017Cited by 41
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapyRong Fan, Jinlin Hou, Siru Zhao et al.|Gut|2024Cited by 22